Am J Psychiatry 161:414-425, March 2004
© 2004 American Psychiatric Association
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Christoph U. Correll, M.D.,
Stefan Leucht, M.D., and
John M. Kane, M.D.
OBJECTIVE: Based on lower rates of acute extrapyramidal side effects associated with second-generation antipsychotics, compared to first-generation antipsychotics, and based on preliminary data, second-generation antipsychotics are expected to cause less tardive dyskinesia than first-generation antipsychotics. This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic. METHOD: Studies of treatment with second-generation antipsychotics lasting  1 year and reporting on new cases of tardive dyskinesia or dyskinesia were systematically reviewed. RESULTS: In 11 studies, 2,769 patients received treatment with risperidone (five studies, N=1,235), olanzapine (two studies, N=610), quetiapine (two studies, N=386), amisulpride (one study, N=331), or ziprasidone (one study, N=207) for a weighted mean and median duration of 263 and 306 days, respectively. Study designs were double blind and randomized (N=3); open-label extensions of double-blind, randomized trials (N=4); and open label (N=4). Of the four trials that had a comparator (all involving adults with schizophrenia spectrum disorders), three used haloperidol (N=408) and one used placebo (N=71). Studied populations included children (N=77), adults (N=1,419), adults and elderly persons (N=794), and exclusively patients age 54 years or older (N=479). The weighted mean annual incidence of tardive dyskinesia for second-generation antipsychotics was 0% in the children, 0.8% (range=0.0%–1.5%) in the adults, 6.8% in the mixed adult and elderly population, and 5.3% (range=0.0%–13.4%) in the patients age 54 years and older, compared to 5.4% (range=4.1%–7.4%) in adults treated with haloperidol. CONCLUSIONS: Results from 11 long-term studies support the idea that second-generation antipsychotics have a reduced risk for tardive dyskinesia, compared to first-generation antipsychotics, although the doses of haloperidol used in the comparator studies were relatively high. More carefully designed studies, ideally lasting beyond 1 year and comparing the effects of different second-generation antipsychotics in patients who have never taken first-generation antipsychotics, are needed to estimate the true risk. It would not appear premature for clinicians to consider these findings in making long-term treatment decisions.
This article has been cited by other articles:
|
|
|
|
 
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv,
May 1, 2008;
59(5):
500 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck, D. L. Leslie, and J. A. Doshi
Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Psychiatr Serv,
May 1, 2008;
59(5):
515 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Law, D. Ross-Degnan, and S. B. Soumerai
Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements
Psychiatr Serv,
May 1, 2008;
59(5):
540 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Alessi-Severini, R. G. Biscontri, D. M. Collins, A. Kozyrskyj, J. Sareen, and M. W. Enns
Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996-2006
Psychiatr Serv,
May 1, 2008;
59(5):
547 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane and S. Leucht
Unanswered Questions in Schizophrenia Clinical Trials
Schizophr Bull,
March 1, 2008;
34(2):
302 - 309.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry,
March 1, 2008;
192(3):
161 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kenney, C. Hunter, A. Davidson, and J. Jankovic
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
379 - 384.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Strutton, B. Gutierrez, and C. M . Blanchette
Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia
Am. J. Health Syst. Pharm.,
January 1, 2008;
65(1):
42 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography Schizophrenia
Focus,
January 1, 2008;
6(2):
197 - 199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Schizophr Bull,
January 1, 2008;
34(1):
60 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Claxton, J. J. Chen, and D. M. Swope
Drug-Induced Movement Disorders
Journal of Pharmacy Practice,
December 1, 2007;
20(6):
415 - 429.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. M. Bratti, J. M. Kane, and S. R. Marder
Chronic Restlessness With Antipsychotics
Am J Psychiatry,
November 1, 2007;
164(11):
1648 - 1654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
The British Journal of Psychiatry,
September 1, 2007;
191(3):
238 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. SOUMERAI and M. R. LAW
Cost-Effectiveness of Schizophrenia Pharmacotherapy
Am J Psychiatry,
April 1, 2007;
164(4):
678 - 678.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. ROSENHECK, T. S. STROUP, M. SWARTZ, J. McEVOY, S. M. DAVIS, R. S.E. KEEFE, J. K. HSIAO, and J. LIEBERMAN
Dr. Rosenheck and Colleagues Reply
Am J Psychiatry,
April 1, 2007;
164(4):
678 - 680.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Damier, S. Thobois, T. Witjas, E. Cuny, P. Derost, S. Raoul, P. Mertens, J.-C. Peragut, J.-J. Lemaire, P. Burbaud, et al.
Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia
Arch Gen Psychiatry,
February 1, 2007;
64(2):
170 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck, D. L. Leslie, J. Sindelar, E. A. Miller, H. Lin, T. S. Stroup, J. McEvoy, S. M. Davis, R. S.E. Keefe, M. Swartz, et al.
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Am J Psychiatry,
December 1, 2006;
163(12):
2080 - 2089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Straker, P. A. Shapiro, and P. R. Muskin
Aripiprazole in the Treatment of Delirium
Psychosomatics,
October 1, 2006;
47(5):
385 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1074 - 1076.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane
Tardive Dyskinesia Circa 2006
Am J Psychiatry,
August 1, 2006;
163(8):
1316 - 1318.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Tenback, P. N. van Harten, C. J. Slooff, J. van Os, and SOHO Study Group
Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Am J Psychiatry,
August 1, 2006;
163(8):
1438 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry,
June 1, 2006;
63(6):
679 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. GHARABAWI, C. A. BOSSIE, and Y. ZHU
New-Onset Tardive Dyskinesia in Patients With First-Episode Psychosis Receiving Risperidone or Haloperidol
Am J Psychiatry,
May 1, 2006;
163(5):
938 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Straker, C. U. Correll, E. Kramer-Ginsberg, N. Abdulhamid, F. Koshy, E. Rubens, R. Saint-Vil, J. M. Kane, and P. Manu
Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications
Am J Psychiatry,
June 1, 2005;
162(6):
1217 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R.E. Barnes
Why indeed?: INVITED COMMENTARY ON... WHY AREN'T DEPOT ANTIPSYCHOTICS PRESCRIBED MORE OFTEN AND WHAT CAN BE DONE ABOUT IT?
Advan. Psychiatr. Treat.,
May 1, 2005;
11(3):
211 - 213.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. SARAF and P. S. CHANDRA
Tardive Dyskinesia and Second-Generation Antipsychotics
Am J Psychiatry,
February 1, 2005;
162(2):
404 - 405.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Psychiatr Serv,
January 1, 2005;
56(1):
85 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
July 1, 2004;
9(4):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted: 06 Feb 2004 to 16 Apr 2004
Evid. Based Nurs.,
July 1, 2004;
7(3):
e3 - e3.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
